Showing 7571-7580 of 8720 results for "".
- Inaugural ElderDerm Conference Hosted by GWhttps://practicaldermatology.com/news/inaugural-elderderm-conference-hosted-gw/2467204/The inaugural ElderDerm Conference was held June 6 in Washington, DC, hosted by the GW Department of Dermatology. Co-Director Adam Friedman, MD, a Practical DermatologyÒ Editorial Board member, presented two talks: “Hair Loss in the Elderly: Considerations and Therapeutic Approaches” and
- Study Reveals Skin Cancer Surveillance Gaps in Transplant Recipientshttps://practicaldermatology.com/news/study-reveals-skin-cancer-surveillance-gaps-transplant-recipients/2467203/
- Dermavant Receives Approval of Tapinarof for Psoriasis and Atopic Dermatitis in Japanhttps://practicaldermatology.com/news/dermavant-receives-approval-tapinarof-psoriasis-and-atopic-dermatitis-japan/2467170/Dermavant Sciences announced that Japan Tobacco has received approval in Japan for tapinarof c
- Event Promotes Anti-Itch Cream for Stopping Pesky Bugs From Disrupting Summer Funhttps://practicaldermatology.com/news/event-promotes-anti-itch-cream-stopping-pesky-bugs-disrupting-summer-fun/2467168/Summer is in full swing and as patients spend more time outdoors, bug bites and other skin irritants will find a way to disrupt the fun.
- Link Between UV Exposure and Cutaneous Angiosarcoma Incidencehttps://practicaldermatology.com/news/link-between-uv-exposure-and-cutaneous-angiosarcoma-incidence/2467139/Ambient ultraviolet radiation (UVR) was associated with a higher incidence of cutaneous angiosarcoma (cAS), an aggressive lymphatic/vascular endothelial-based cancer. Researchers publishing the findings in a research letter in Journal of the American Academy of Dermatology (JAAD)<
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J
- Recurrence in Patients with Thin Melanomas Linked with Poor Prognosis, Despite Rarityhttps://practicaldermatology.com/news/recurrence-patients-thin-melanomas-linked-poor-prognosis-despite-rarity/2467070/While rare, the recurrence of melanomas in patients with thin melanomas was linked with poorer prognosis and lower survival rates, a single-center analysis reported. "The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm)," the researchers wrote in their study, publi
- Ruxolitinib cream 1.5% Demonstrates Tolerability, Safety Over 52 Weeks in Childrenhttps://practicaldermatology.com/news/ruxolitinib-cream-15-demonstrates-tolerability-safety-over-52-weeks-children/2467044/Ruxolitinib cream 1.5% demonstrated consistently good tolerability and safety over 52 weeks in children 2 to 11 years old with extensive moderate-to-severe atopic dermatitis (AD) in a study presented this month at the Revolutionizing Atopic Dermatitis (RAD) Conference in Chicago, Illinois.
- Moderate-to-Severe AA Linked to AD Comorbidityhttps://practicaldermatology.com/news/moderate-severe-aa-linked-ad-comorbidity/2467042/Patients with moderate-to-severe alopecia areata (AA) had higher prevalence and incidence of atopic dermatitis (AD) comorbidity and higher prevalence of moderate-to-severe AD than those with mild AA in a study presented this month at the Revolutionizing Alopecia, Vitligo, and Eczema (RAVE) Confer
- INTEGUMENT-OLE: Efficacy and Safety of Roflumilast Cream 0.15% in AD Maintained to 56 Weekshttps://practicaldermatology.com/news/integument-ole-efficacy-and-safety-roflumilast-cream-ad-maintained-56-weeks/2467010/Results from the INTEGUMENT-OLE long-term study suggested that roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) is effective and well-tolerated over a treatment period of up to 56 weeks in adults and children aged six years and older. Researchers for the open-label study